Search Results 521-530 of 18377 for alopecia

1. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

2. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

3. A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - Mayo Clinic

   * Lupus headache, alopecia, organic brain syndrome, and mucosal ulcers must be recorded on SLEDAI 2K, if indicated, but do not count toward the points ...

4. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

5. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

6. A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer Patients - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1),with the exception of alopecia, ...

7. A Study to Evaluate Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC - Mayo Clinic

   Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

8. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

   03) except for subjects with alopecia; subjects receiving luteinizing hormone-releasing hormone agonists may be considered for enrollment after discussion with ...

9. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer - Mayo Clinic

   Recovered from the toxic effects of radiation treatment before study entry, except for alopecia. Absolute neutrophil count (ANC) ≥ 1500 uL; Platelets (PLT) ...

10. A First in Man Trial for Patients With Cancer - Mayo Clinic

    Recovery from adverse effects of prior therapy at time of enrollment to o ≤ Grade 1 (excluding alopecia); Agreement to forego any other chemotherapy ...